Activity Title: 2018 Virtual Symposium: Cardiovascular Risk Reduction in T2DM: Applying the Trial Data to Clinical Practice
Activity Format: Virtual Symposium
Program Description:
Death from CV disease is 70% higher in adults with diabetes compared to those without diabetes, and patients with diabetes have a decreased life expectancy, mostly due to premature CV death. Evidence is accumulating that other factors besides impaired glucose metabolism play a role in the pathophysiology of T2DM and that a comprehensive approach against insulin resistance, obesity, hypertension, and dyslipidemia in addition to diet and exercise is required. In addition, because certain pharmacologic therapies were found to increase the risk of CV events, all new drugs introduced since 2008 have been mandated by the FDA to undergo CV safety outcome trials (CVOT) in high-risk T2DM patients. As a result, a growing body of evidence is accumulating on the effectiveness of several antihyperglycemic agents to reduce CV mortality, overall mortality, and hospitalizations for worsening heart failure in high-risk patients with T2DM.
In this virtual symposium, recorded from the 13th Annual Cardiometabolic Health Congress, experts will utilize a unique, infographic teaching format to review the latest cardiovascular outcomes studies of current antihyperglycemic therapies and compare the risks vs benefits as well as how to incorporate them into an individualized treatment plan for clinicians who treat patients with T2DM who are at a high risk for CVD.
Estimated Time to Complete: 1.0 hours
Release Date: January 11, 2019
Expiration Date: January 11, 2020
Credit Type(s) Available: ACCME, CDR, ACPE, ANCC
Maximum Credits: 1.0 hour
Provided By: This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.
Commercial Supporter:
This activity is supported by educational grants from AstraZeneca and Novo Nordisk.
Intended Audience:
US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
Educational Objectives:
Upon completion of this activity, participants should be able to:
- Describe comorbidities of CVD among patients with T2DM, including the prevalence and burden
- Summarize current and emerging CV outcomes trials on SGLT2 inhibitors and GLP1-RAs in T2DM patients
- Incorporate evidence from recent CVOTs to develop T2DM treatment plans that improve glycemic control and reduce CV risk when appropriate based on guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences
Faculty Information:
Robert H. Eckel, MD (Chair)
- Professor of Medicine
- Division of Endocrinology, Metabolism and Diabetes
- Division of Cardiology
- Professor of Physiology and Biophysics
- Charles A. Boettcher II Chair in Atherosclerosis
- Director, T32 in Obesity and Cardiovascular Disease
- University of Colorado Anschutz Medical Campus
- Director, Lipid Clinic, University Hospital
- Aurora, CO
Consultant/Independent Contractor: Sanofi/Regeneron, Novo Nordisk
Deepak L. Bhatt, MD, MPH
- Professor of Medicine
- Harvard Medical School
- Executive Director
- Interventional Cardiovascular Programs
- Brigham and Women's Hospital Heart and Vascular Center
- Boston, MA
Research Funding: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company
Harold E. Bays, MD
- Medical Director/President
- Louisville Metabolic and Atherosclerosis
- Research Center, Inc.
- Louisville, KY
Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Eisai, Janssen, Johnson & Johnson, Merck, Novo Nordisk
Consultant/Independent Contractor: AstraZeneca, Boehringer Ingelheim, Janssen, Johnson & Johnson
Lawrence Blonde, MD
- Director, Ochsner Diabetes Clinical Research Unit
- Frank Riddick Diabetes Institute
- Department of Endocrinology
- Ochsner Medical Center
- New Orleans, LA
Consultant/Independent Contractor: Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi
Grant/Research Support: Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk, and Sanofi
Speaker's Bureau: AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk, and Sanofi
Disclosure of Conflicts of Interest:
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Accreditor Disclosures:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN; Lindsay Borvansky; Andrea Funk; Amanda Turner; Erin Franceschini, MS; Karin McAdams all have nothing to disclose.
Accreditation:
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement(s):
Physician Credit Designation
Global Education Group designates this virtual activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
There are 1.0 pharmacotherapy hours available for this activity.
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-430-H01-P
Dietician Accreditation Statement
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials.
CPE Provider #GE012
Global Contact Information:
For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com
Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions for CME/CE Credit:
This activity is offered at no cost to participants. During the period January 11, 2019 through January 11, 2020, participants must follow these steps in order to receive CME/CE credit:
- Sign In or Register at https://www.cardiometabolichealth.org/my-account.html
- Read and accept the Terms & Conditions including the learning objectives and faculty disclosures.
- Complete the pre-test by recording the best answer to each question in the answer key. There is no scoring of the pre-test questions section.
- Review the educational activity.
- Complete the post-test by recording the best answer to each question in the answer key. Successful completion of the post-test is required to earn CME/CE credit. Successful completion is defined as a cumulative score of at least 70%.
- Complete the online evaluation form.
- After successfully completing the post-test and online evaluation form, your CME/CE certificate will be generated and will be available immediately for print.
Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6-10 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed.
For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or cme@globaleducationgroup.com.
Disclaimer:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Hardware and Software Requirements:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.
